Repligen, MIT Sue ImClone Over Erbitux Patent

Law360, New York (May 5, 2004, 12:00 AM EDT) -- A drug maker and a university are suing Manhattan-based biotech company ImClone over patent rights to the drug at the center of the scandal that led to the trials of ImClone founder Sam Waksal and domestic diva Martha Stewart.

Repligen Corp., a Waltham, Mass.-based drug developer, and the Massachusetts Institute of Technology have filed a patent infringement suit against ImClone in the U.S. District Court for the District of Massachusetts, seeking royalties from sales of cancer drug Erbitux.

The complaint alleges that ImClone's manufacturing process for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.